Kidney International

Article	Citations
Kidney disease is associated with in-hospital death of patients with COVID-19	1828
Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China	1241
Acute kidney injury in patients hospitalized with COVID-19	986
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases	699
KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease	587
The Novel Coronavirus 2019 epidemic and kidneys	441
KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease	438
Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference	391
Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe	367
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases	326
A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia	289
COVID-19 infection in kidney transplant recipients	276
The case of complement activation in COVID-19 multiorgan impact	254
Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference	251
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease	242
COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain	240
Collapsing glomerulopathy in a COVID-19 patient	228
An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants	194
Outcomes of patients with end-stage kidney disease hospitalized with COVID-19	190
The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference	190
Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment	184
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy	179
A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection	168
SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule	165
Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease	163

Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference	159
Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine	159
Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease	150
Semaphorin 3B–associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients	134
Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease	122
Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference	122
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment	118
Weak anti–SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients	116
Thrombotic microangiopathy in a patient with COVID-19	116
Molecular mechanisms and therapeutic targets for diabetic kidney disease	114
Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial	108
The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?	107
Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients	106
The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy	104
After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy	102
NELL1 is a target antigen in malignancy-associated membranous nephropathy	102
Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference	100
Development and evaluation of deep learning–based segmentation of histologic structures in the kidney cortex with multiple histologic stains	99
Occurrence of severe COVID-19 in vaccinated transplant patients	99
COVID-19 infection in kidney transplant recipients at the epicenter of pandemics	98
A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant	97
Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients	95
A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syn	93
ANCA glomerulonephritis after the Moderna COVID-19 vaccination	92
Visualization of putative coronavirus in kidney	92
Rationale and design of the Kidney Precision Medicine Project	91
Hyperuricemia as a trigger of immune response in hypertension and chronic kidney disease	90
Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis	90
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice	90
Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy	88
A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 Disease (COVID-19)	86
Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis	85
IMPact of the COVID-19 epidemic on the moRTAlity of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT)	84
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglob	82
Repression of the antiporter SLC7A11/glutathione/glutathione peroxidase 4 axis drives ferroptosis of vascular smooth muscle cells to facilitate vascular calcification	81
COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment	80
A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination	80
Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine	79
A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis	78
Tubule-derived exosomes play a central role in fibroblast activation and kidney fibrosis	78
Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence	78
Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease due to mutations in UMOD and MUC1	73
The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease	73
Intestinal microbiota control acute kidney injury severity by immune modulation	72
Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients	72
The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action	71
The eye, the kidney, and cardiovascular disease: old concepts, better tools, and new horizons	71
A bidirectional Mendelian randomization study supports causal effects of kidney function on blood pressure	70
A prospective cohort study of acute kidney injury and kidney outcomes, cardiovascular events, and death	70
Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes	70

Multivesicular bodies mimicking SARS-CoV-2 in patients without COVID-19	68
Thirty years of the International Banff Classification for Allograft Pathology: the past, present, and future of kidney transplant diagnostics	67
De novo vasculitis after mRNA-1273 (Moderna) vaccination	66
Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)	66
Allorecognition and the spectrum of kidney transplant rejection	66
A novel mouse model of phospholipase A2 receptor 1-associated membranous nephropathy mimics podocyte injury in patients	65
Is COVID-19 vaccination unmasking glomerulonephritis?	65
International consensus definitions of clinical trial outcomes for kidney failure: 2020	64
COVID-19 vaccination followed by activation of glomerular diseases: does association equal causation?	63
Calciprotein particles regulate fibroblast growth factor-23 expression in osteoblasts	63
Tubuloreticular inclusions in COVID-19–related collapsing glomerulopathy	61
SARS-CoV-2 receptor networks in diabetic and COVID-19–associated kidney disease	61
Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy	60
A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis	59
Cystinuria: clinical practice recommendation	57
A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response	57
Selective nanoparticle-mediated targeting of renal tubular Toll-like receptor 9 attenuates ischemic acute kidney injury	57
IgA nephropathy presenting as macroscopic hematuria in 2 pediatric patients after receiving the Pfizer COVID-19 vaccine	57
Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection	57
The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis	57
Artificial intelligence and machine learning in nephropathology	56
Ultrasound super-resolution imaging provides a noninvasive assessment of renal microvasculature changes during mouse acute kidney injury	55
Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) study	55
Establishing core outcome domains in pediatric kidney disease: report of the Standardized Outcomes in Nephrology—Children and Adolescents (SONG-KIDS) consensus workshops	55
Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome	54
Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy	54
Anti–glomerular basement membrane disease during the COVID-19 pandemic	54
Relapse of primary membranous nephropathy after inactivated SARS-CoV-2 virus vaccination	53
A practical guide to multiple imputation of missing data in nephrology	53
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function	52
Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy	52
Managing the COVID-19 pandemic: international comparisons in dialysis patients	52
Electron microscopic investigations in COVID-19: not all crowns are coronas	51
The ketone body β-hydroxybutyrate mitigates the senescence response of glomerular podocytes to diabetic insults	51
Diagnosis and management of Bartter syndrome: executive summary of the consensus and recommendations from the European Rare Kidney Disease Reference Network Working Group for Tubular Disorders	51
Epitopes as characterized by antibody-verified eplet mismatches determine risk of kidney transplant loss	51
Developmental stages of tertiary lymphoid tissue reflect local injury and inflammation in mouse and human kidneys	50
Blockade of SARS-CoV-2 infection by recombinant soluble ACE2	50
Exosome-based delivery of super-repressor IκBα ameliorates kidney ischemia-reperfusion injury	49
Prolyl hydroxylase inhibition protects the kidneys from ischemia via upregulation of glycogen storage	49
Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD)	48
A case of ANCA-associated vasculitis after AZD1222 (Oxford–AstraZeneca) SARS-CoV-2 vaccination: casualty or causality?	47
Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving hemodialysis: a call to arms	47
Development and testing of an artificial intelligence tool for predicting end-stage kidney disease in patients with immunoglobulin A nephropathy	47
Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis	47
Dephosphorylation of AMP-activated protein kinase exacerbates ischemia/reperfusion-induced acute kidney injury via mitochondrial dysfunction	46
Genetic testing for kidney disease of unknown etiology	46
Executive summary for China Kidney Disease Network (CK-NET) 2016 Annual Data Report	45
Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes	45
New-onset systemic lupus erythematosus beginning as class V lupus nephritis after COVID-19 vaccination	45
A randomized multicenter trial on a lung ultrasound–guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk	45
Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients	45
Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria	45
Genetics in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference	45
A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout	44
Annexin A1 alleviates kidney injury by promoting the resolution of inflammation in diabetic nephropathy	44
Anti-GBM nephritis with mesangial IgA deposits after SARS-CoV-2 mRNA vaccination	44
Podocyte-specific Nlrp3 inflammasome activation promotes diabetic kidney disease	43
Histologic correlates of gross hematuria following Moderna COVID-19 vaccine in patients with IgA nephropathy	42
New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction	42
Waning humoral response 6 months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis patients: time for a boost	42
Atypical HUS relapse triggered by COVID-19	41
AI applications in renal pathology	41
Genetic or pharmacologic Nrf2 activation increases proteinuria in chronic kidney disease in mice	41
Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline	41
The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment	41
A Mendelian randomization study found causal linkage between telomere attrition and chronic kidney disease	41
Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine	41
Tenascin-C promotes acute kidney injury to chronic kidney disease progression by impairing tubular integrity via αvβ6 integrin signaling	40
Consensus definitions for glomerular lesions by light and electron microscopy: recommendations from a working group of the Renal Pathology Society	40
Early experience with COVID-19 in kidney transplantation	40
Diagnosis and treatment of arterial hypertension 2021	40
Blocking matrix metalloproteinase-mediated syndecan-4 shedding restores the endothelial glycocalyx and glomerular filtration barrier function in early diabetic kidney disease	40
A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients	40
In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarke	40
Acute kidney injury in pediatric patients hospitalized with acute COVID-19 and multisystem inflammatory syndrome in children associated with COVID-19	39
Trajectories of glomerular filtration rate and progression to end stage kidney disease after kidney transplantation	39
Changes in kidney function follow living donor nephrectomy	39
IL-6-mediated hepatocyte production is the primary source of plasma and urine neutrophil gelatinase–associated lipocalin during acute kidney injury	39
Relapse of class V lupus nephritis after vaccination with COVID-19 mRNA vaccine	39

Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won	38
Genetic reduction of cilium length by targeting intraflagellar transport 88 protein impedes kidney and liver cyst formation in mouse models of autosomal polycystic kidney disease	38
Refining genotype–phenotype correlations in 304 patients with autosomal recessive polycystic kidney disease and PKHD1 gene variants	38
Nuclear farnesoid X receptor attenuates acute kidney injury through fatty acid oxidation	38
Global microRNA profiling in human urinary exosomes reveals novel disease biomarkers and cellular pathways for autosomal dominant polycystic kidney disease	38
A randomized controlled trial to investigate the effects of intra-dialytic cycling on left ventricular mass	38
Empagliflozin restores chronic kidney disease–induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction	37
The lupus nephritis management renaissance	37
Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment	37
Clinical spectrum, prognosis and estimated prevalence of DNAJB11-kidney disease	37
Common risk variants in NPHS1 and TNFSF15 are associated with childhood steroid-sensitive nephrotic syndrome	36
Efficacy of anti–SARS-CoV-2 monoclonal antibody prophylaxis and vaccination on the Omicron variant of COVID-19 in kidney transplant recipients	36
Electronic health records for the diagnosis of rare diseases	36
Mesenchymal stromal cell–based therapies for acute kidney injury: progress in the last decade	36
Lysophosphatidylcholine mediates fast decline in kidney function in diabetic kidney disease	36
A third vaccine dose substantially improves humoral and cellular SARS-CoV-2 immunity in renal transplant recipients with primary humoral nonresponse	36
Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease	36
Suboptimal antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients	36
Human kidney organoids produce functional renin	35
Significance of HLA-DQ in kidney transplantation: time to reevaluate human leukocyte antigen–matching priorities to improve transplant outcomes? An expert review and recommendations	35
Proteinuric chronic kidney disease is associated with altered red blood cell lifespan, deformability and metabolism	35
Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre-clinical model	35
Acute rejection after anti–SARS-CoV-2 mRNA vaccination in a patient who underwent a kidney transplant	35
Role of direct oral anticoagulants in patients with kidney disease	34
Differential expression of microRNA miR-150-5p in IgA nephropathy as a potential mediator and marker of disease progression	34
Targeting energy pathways in kidney disease: the roles of sirtuins, AMPK, and PGC1α	34
Minimal change disease relapse following SARS-CoV-2 mRNA vaccine	34
Lithocholic acid increases intestinal phosphate and calcium absorption in a vitamin D receptor dependent but transcellular pathway independent manner	34
Living well with kidney disease by patient and care-partner empowerment: kidney health for everyone everywhere	34
The spectrum of kidney biopsy findings in HIV-infected patients in the modern era	34
A prospective controlled study of metabolic and physiologic effects of kidney donation suggests that donors retain stable kidney function over the first nine years	33
Diphenhydramine may be a preventive medicine against cisplatin-induced kidney toxicity	33
Granulomatous vasculitis after the AstraZeneca anti–SARS-CoV-2 vaccine	33
Acute kidney injury with gross hematuria and IgA nephropathy after COVID-19 vaccination	33
Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring	33
The circadian clock is disrupted in mice with adenine-induced tubulointerstitial nephropathy	33
Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool	33
Anti-CD20–mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives	32
SARS-CoV-2 in the peritoneal waste in a patient treated with peritoneal dialysis	32
Estimation of the glomerular filtration rate in children and young adults by means of the CKD-EPI equation with age-adjusted creatinine values	32
SGLT-2 inhibition in IgA nephropathy: the new standard of care?	32
Relapse of minimal change disease following the AstraZeneca COVID-19 vaccine	32
COVID-19 in dialysis patients: outlasting and outsmarting a pandemic	32
Early subclinical tubulitis and interstitial inflammation in kidney transplantation have adverse clinical implications	31
A case of membranous nephropathy following Pfizer–BioNTech mRNA vaccination against COVID-19	31
Supplemented ERA-EDTA Registry data evaluated the frequency of dialysis, kidney transplantation, and comprehensive conservative management for patients with kidney failure in Europe	31
Post-vaccinal minimal change disease	31
Different subpopulations of kidney interstitial cells produce erythropoietin and factors supporting tissue oxygenation in response to hypoxia in vivo	31
Targeting inflammation to treat diabetic kidney disease: the road to 2030	31
Results from the TRIBE-AKI Study found associations between post-operative blood biomarkers and risk of chronic kidney disease after cardiac surgery	31
The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1RC/RC mouse model of autosomal dominant polycystic kidney disease	31
The prevalence of chronic kidney disease in Iceland according to KDIGO criteria and age-adapted estimated glomerular filtration rate thresholds	31
Impaired angiotensin II type 1 receptor signaling contributes to sepsis-induced acute kidney injury	31
Cannabinoid receptor type 2 promotes kidney fibrosis through orchestrating β-catenin signaling	31
Modulation of iron homeostasis with hepcidin ameliorates spontaneous murine lupus nephritis	30
Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy	30
Relapse of IgG4-related nephritis following mRNA COVID-19 vaccine	30
An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis	30
Renal TNFα activates the WNK phosphorylation cascade and contributes to salt-sensitive hypertension in chronic kidney disease	30
COVID-19 morbidity decreases with tixagevimab–cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders	29
Decline and loss of anti–SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection	29
The clinicopathologic spectrum of segmental membranous glomerulopathy	29
Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function	29
EOS789, a novel pan-phosphate transporter inhibitor, is effective for the treatment of chronic kidney disease–mineral bone disorder	29
COVID-19 therapeutic options for patients with kidney disease	29
Management of acute kidney injury in symptomatic multiple myeloma	29
High rates of long-term renal recovery in survivors of coronavirus disease 2019–associated acute kidney injury requiring kidney replacement therapy	29
Deep learning identified pathological abnormalities predictive of graft loss in kidney transplant biopsies	28
A multicenter randomized controlled trial indicates that paclitaxel-coated balloons provide no benefit for arteriovenous fistulas	28
Practical management of C3 glomerulopathy and Ig-mediated MPGN: facts and uncertainties	28
Comparison of BNT162b2 (Pfizer–BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients	28
KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer	28
Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant	28
Could ferritin help the screening for COVID-19 in hemodialysis patients?	28
A multicenter feasibility randomized controlled trial to assess the impact of incremental versus conventional initiation of hemodialysis on residual kidney function	28
The time of onset of intradialytic hypotension during a hemodialysis session associates with clinical parameters and mortality	28
Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis	27
An international cohort study of autosomal dominant tubulointerstitial kidney disease due to mutations identifies distinct clinical subtypes	27
Loss of proximal tubular transcription factor Krüppel-like factor 15 exacerbates kidney injury through loss of fatty acid oxidation	27
Immunotactoid glomerulopathy is a rare entity with monoclonal and polyclonal variants	27
PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2	27
Modulation of transforming growth factor-β-induced kidney fibrosis by leucine-rich ⍺-2 glycoprotein-1	27
Sterol-O-acyltransferase-1 has a role in kidney disease associated with diabetes and Alport syndrome	27
Receptor activator of NF-κB mediates podocyte injury in diabetic nephropathy	27
Updating the International IgA Nephropathy Prediction Tool for use in children	26
Klotho-derived peptide 6 ameliorates diabetic kidney disease by targeting Wnt/β-catenin signaling	26
Central and peripheral arterial diseases in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference	26
Lipoic acid supplementation associated with neural epidermal growth factor-like 1 (NELL1)–associated membranous nephropathy	26
Highly multiplexed immunofluorescence of the human kidney using co-detection by indexing	26
Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model	26
Simultaneous glomerular filtration rate determination using inulin, iohexol, and 99mTc-DTPA demonstrates the need for customized measurement protocols	25
Sodium thiosulfate improves renal function and oxygenation in L-NNA–induced hypertension in rats	25
Membranous nephropathy following anti–COVID-19 mRNA vaccination	25
Best practices for correctly identifying coronavirus by transmission electron microscopy	25
EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients	25